- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-TNFL9/ 4-1BBL/ TNFSF9 monoclonal antibody
Anti-TNFL9/ 4-1BBL/ TNFSF9 antibody for FACS & in-vivo assay
Go to 4-1BBL/TNFSF9 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-IO001-Ab-1/ GM-Tg-hg-IO001-Ab-2 | Anti-Human 4-1BBL/TNFSF9 monoclonal antibody | Human |
| GM-Tg-rg-IO001-Ab-1/ GM-Tg-rg-IO001-Ab-2 | Anti-Rat 4-1BBL/TNFSF9 monoclonal antibody | Rat |
| GM-Tg-mg-IO001-Ab-1/ GM-Tg-mg-IO001-Ab-2 | Anti-Mouse 4-1BBL/TNFSF9 monoclonal antibody | Mouse |
| GM-Tg-cynog-IO001-Ab-1/ GM-Tg-cynog-IO001-Ab-2 | Anti-Cynomolgus/ Rhesus macaque 4-1BBL/TNFSF9 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-IO001-Ab-1/ GM-Tg-felg-IO001-Ab-2 | Anti-Feline 4-1BBL/TNFSF9 monoclonal antibody | Feline |
| GM-Tg-cang-IO001-Ab-1/ GM-Tg-cang-IO001-Ab-2 | Anti-Canine 4-1BBL/TNFSF9 monoclonal antibody | Canine |
| GM-Tg-bovg-IO001-Ab-1/ GM-Tg-bovg-IO001-Ab-2 | Anti-Bovine 4-1BBL/TNFSF9 monoclonal antibody | Bovine |
| GM-Tg-equg-IO001-Ab-1/ GM-Tg-equg-IO001-Ab-2 | Anti-Equine 4-1BBL/TNFSF9 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-IO001-Ab-1/ GM-Tg-hg-IO001-Ab-2; GM-Tg-rg-IO001-Ab-1/ GM-Tg-rg-IO001-Ab-2; GM-Tg-mg-IO001-Ab-1/ GM-Tg-mg-IO001-Ab-2; GM-Tg-cynog-IO001-Ab-1/ GM-Tg-cynog-IO001-Ab-2; GM-Tg-felg-IO001-Ab-1/ GM-Tg-felg-IO001-Ab-2; GM-Tg-cang-IO001-Ab-1/ GM-Tg-cang-IO001-Ab-2; GM-Tg-bovg-IO001-Ab-1/ GM-Tg-bovg-IO001-Ab-2; GM-Tg-equg-IO001-Ab-1/ GM-Tg-equg-IO001-Ab-2 |
| Products Name | Anti-4-1BBL/TNFSF9 monoclonal antibody |
| Format | mab |
| Target Name | 4-1BBL |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-4-1BBL benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation | Lyophilized from sterile PBS, PH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | Products Developing | Multi-species TNFL9/ 4-1BBL/ TNFSF9 VLP (virus-like particle) (Products Developing) |
| Cytokine | GM-Tg-g-IO001-Ag-1 | tumor necrosis factor (ligand) superfamily, member 9 (TNFSF9) protein |
| ORF Viral Vector | pGMLV000252 | human TNFSF9 Lentivirus plasmid |
| ORF Viral Vector | vGMLV000252 | human TNFSF9 Lentivirus particle |
| ORF Viral Vector | pGMLPm001942 | mouse Tnfsf9 Lentivirus plasmid |
| ORF Viral Vector | vGMLPm001942 | mouse Tnfsf9 Lentivirus particle |
Target information
| Target ID | GM-IO001 |
| Target Name | 4-1BBL |
| Gene ID | 8744,21950,353218,700588,476729,101087207,521748,102150292 |
| Gene Symbol and Synonyms | 4-1BB-L,4-1BBL,CD137L,Ly63l,TNFSF9,TNLG5A |
| Uniprot Accession | P41273,P41274 |
| Uniprot Entry Name | TNFL9_HUMAN,TNFL9_MOUSE |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target, Immuno-oncology Target, Cytokine Target |
| Disease | N/A |
| Gene Ensembl | ENSG00000125657 |
| Target Classification | Checkpoint-Immuno Oncology |
The target: 4-1BBL, gene name: TNFSF9, also named as 4-1BB-L, CD137L, TNLG5A. The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This transmembrane cytokine is a bidirectional signal transducer that acts as a ligand for TNFRSF9/4-1BB, which is a costimulatory receptor molecule in T lymphocytes. This cytokine and its receptor are involved in the antigen presentation process and in the generation of cytotoxic T cells. The receptor TNFRSF9/4-1BB is absent from resting T lymphocytes but rapidly expressed upon antigenic stimulation. The ligand encoded by this gene, TNFSF9/4-1BBL, has been shown to reactivate anergic T lymphocytes in addition to promoting T lymphocyte proliferation. This cytokine has also been shown to be required for the optimal CD8 responses in CD8 T cells. This cytokine is expressed in carcinoma cell lines, and is thought to be involved in T cell-tumor cell interaction.[provided by RefSeq, Oct 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
